What is the clinical performance of the Pathwork Tissue of Origin LDT?
The Pathwork Tissue of Origin LDT is supported by extensive analytical and clinical validation data. • In 462 FFPE specimens, the test demonstrated 89% positive percent agreement (akin to sensitivity) with available diagnoses, and greater than 99% negative percent agreement (akin to specificity) in specimens that had previously been identified with existing methods as being among the 15 tumor types on the panel3.
